Managing sickle cell disease

British Medical Journal

Volumn 327, Issue 7424, 2003, Pages 1151-1155

  Claster, Susan ^a   Vichinsky, Elliott P ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,2 BIS(4 FLUOROPHENYL) 2 PHENYLACETAMIDE; 5 AZA 2' DEOXYCYTIDINE; ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIANDROGEN; ANTISICKLING AGENT; BUTYRIC ACID; CLOTRIMAZOLE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYUREA; MACROLIDE; MAGNESIUM; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANALGESIA; ANTIBIOTIC PROPHYLAXIS; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CONTRACEPTIVE DEVICE; DOPPLER ECHOGRAPHY; ERYTHROCYTE TRANSFUSION; GENETIC COUNSELING; HAND FOOT SYNDROME; HUMAN; INFLUENZA; INFLUENZA VACCINATION; KIDNEY DISEASE; LIFE EXPECTANCY; LIFESPAN; MULTIPLE ORGAN FAILURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCREENING TEST; SICKLE CELL ANEMIA; SICKLE CELL TRAIT; SYMPTOM; TREATMENT PLANNING;

EID: 0242552237     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.327.7424.1151     Document Type: Review

References (36)

1. Stuart MJ, Setty BN. Acute chest syndrome of sickle cell disease: new light on an old problem. Curr Opin Hematol 2001;8(2):111-22.
2. Hagar RW, Vichinsky EP. Major changes in sickle cell disease. Adv Pediatr 2000;47:249-72.
3. Vichinsky E, Hurst D, Earles A, Kleman K, Lubin B. Newborn screening for sickle cell disease: effect on mortality. Pediatrics 1988;81:749-55.
4. Benjamin LJ, Swinson GI, Nagel RL. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises. Blood 2000;95:1130-6,
5. National Institutes of Health, National Heart, Lung, and Blood Institute, and Division of Blood Diseases and Resources, The management of sickle cell disease. Bethesda, MD: NIH. (NTH Publication No 02-2117.)
6. Smith J, Espeland M, Bellevue R, Bonds D, Brown AK, Koshy M. Pregnancy in sickle cell disease: experience of the Cooperative Study of Sickle Cell Disease. Obstet Gynecol 1996;87:199-204.
7. Miller S, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000;342:1612-3.
8. Section on Hematology/Oncology Committee on Genetics; American Academy of Pediatrics. Health supervision for children sickle cell disease. Pediatrics 2002;109:526-35.
9. Falletta JM, Woods GM, Verter JI, Buchanan GR, Pegelow CH, Iyer RV, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. J Pediatr 1995;127:685-90.
10. Hord J, Byrd R, Stowe L. Streptococcus pneumoniae sepsis and meningitis during the penicillin prophylaxis era in children with sickle cell disease. J Pediatr Hematol Oncol 2002;24:470-2.
11. Ohene-Frempong K. Stroke in sickle cell disease: demographic, clinical, and therapeutic considerations. Semin Hematol 1991;28:213-9.
12. Adams RJ, Mckie VC, Bramilla D, Carl E, Gallagher D, Nichols FT, et al. Stroke prevention trial in sickle cell anemia. Control Clin Trials 1998;19:110-29.
13. Ballas S. Ethical issues in the management of sickle cell pain. Am J Hematol 2001;68:127-32.
14. Vichinsky E, ed. Transfusion-related iron overload in sickle cell anemia. Seminars in hematology, ed. NS Young and P Beris. Vol 38(No 1, Suppl 1):1-5, 14-23. Philadelphia, PA: Harcourt Health Sciences, 2001.
15. Miller ST, Macklin EA, Pegelow CH, Kinney TR, Sleeper LA, Bello JA, et al. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr 2001;39:385-90.
16. Moser FG, Miller ST, Bello JA, Pegelow CH, Zimmerman RA, Wang WC, et al. The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease. Am J Neuroradiol 1996;17:965-72.
17. Styles LA, Vichinsky EP. Core decompression in avascular necrosis of the hip in sickle-cell disease. Am J Hematol 1996;52:103-7.
18. Ataga KI, Orringer E. Renal abnormalities in sickle cell disease. Am J Hematol 2000;63:205-11.
19. Abbott KC, Hypolite IO, Agodoa LY. Sickle cell nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 2002;58:9-15.
20. Vichinsky EP. New therapies in sickle cell disease. Lancet 2002;360:629-31.
21. Okpala I, Westerdale N, Jegede T, Cheung B. Etilefrine for the prevention of priapism in adult sickle cell disease. Br J Haematol 2002;118:918-21.
22. Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood 1997;89:1787-92.
23. Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette CT, Dean D, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000;342:1855-65.
24. Dean D, Neumayr L, Kelly DM, Ballas SK, Kleman K, Roberston S, et al. Chlamydia pneumoniae and acute chest syndrome in patients with sickle cell disease. J Pediatr Hematol Oncol 2003;25:46-55.
25. Castro OL, Hoque M, Brown BD. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood 2002.3:3.
26. Young NS, Beris P, eds. New therapies of sickle cell anemia and B-thalassemia. Seminars in hematology, ed. GP Rodgers and EA Rachmilewitz. Vol 38. Philadelphia, PA: Harcourt Health Sciences, 2001:435.
27. Morris CR. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Blood 2000;6(11):(Suppl, part 1)485a.
28. Styles LA, Vichinsky E. Effects of a long-term transfusion regimen on sickle cell-related illnesses. J Pediatr 1994;125(6 Pt 1):909-11.
29. Schmalzer EA, Lee JO, Brown AK, Usami S, Chion S. Viscosity of mixtures of sickle cells and normal red cells at varying hematocrit levels: implications for transfusion. Transfusion 1987;1987:228-33.
30. Brittenham GM, Cohen AR, McLaren CE, Martin MB, Griffith PM, Nienhuis AW et al. Hepatic iron stores and plasma ferritin concentrationin patients with sickle cell anemia and thalassemia major. Am J Hematol 1993;42:81-5.
31. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky EP, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991;325:11-6.
32. Vichinsky EP. Comprehensive care in sickle cell disease: its impact on morbidity and mortality. Semin Hematol 1991;28:220-6.
33. Olivieri NF, Vichinsky EP. Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. J Pediatr Hematol Oncol 1998;20:26-31.
34. Charache S, Terrin ML, Moore RD, Dover GJ, McMahon RP, Barlow FB, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317-22.
35. Morris CR, Kuypers FA, Larkin S, Sweeters N, Simon J, Vichinsky EP, et al. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br J Haematol 2000;111:498-500.
36. Walters MC, Storb R, Patience M, Leisenring W, Taylor T, Sanders JE, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 2000;95:1918-24.